eversyn secures €1.6 million in seed funding to scale up production and accelerate technology applications in nutrition and biopharma

Bridging the Gap in High-Value, Complex Glycan Accessibility

The nutrition and biopharmaceutical sectors are experiencing unprecedented growth, driven by increasing health awareness, aging populations, and the prevalence of non-communicable chronic diseases. eversyn’s technology addresses the limitations faced by traditional cell-based approaches in these industries. The start-up’s cell-free enzymatic approach allows for optimization of complex biosynthetic pathways without the constraints of cellular metabolism. This technology enables the production of high-value, complex glycans with unprecedented efficiency and flexibility, potentially revolutionizing the development of nutritional products and biopharmaceuticals.

Dr. Thomas Rexer, CEO and co-founder of eversyn, stated: “This funding round marks a pivotal moment in eversyn’s journey, providing us with the resources needed to scale our production capabilities and bring our transformative technology to market more rapidly. We are particularly excited about the opportunities this creates to address pressing challenges in nutrition and biopharma, where our solutions can deliver significant value to society. The support from Max Planck Innovation GmbH over the past years, with respect to patenting, founding, and acquiring grants and investments, has been essential in helping us to advance our mission. Moreover, without the excellent support through the EXIST Transfer of Research programs, both in terms of funding and start-up advice, we could not have achieved this point.”

Investor Support and Scientific Backing

The investment round garnered strong support from both financial and scientific institutions, underscoring the potential impact of eversyn’s technology.

Philipp Kopp, Investment Manager at bmp Ventures, commented: “eversyn’s innovative approach to nutrition and biopharmaceuticals addresses critical market needs with a scalable technology platform. The team’s deep technical expertise and clear vision for commercialization were key factors in our decision to invest.”

Dr. Axel Nemetz, Managing Director at MPF Start-up Accelerator: “We strongly believe in eversyn’s vision and technology. Their robust patent portfolio significantly lowers manufacturing costs—by nearly an order of magnitude—for essential glycan building blocks. This enables unprecedented commercial feasibility for producing critical components required in biopharma and nutrition to accelerate the development of next-generation therapeutics and human milk oligosaccharides used in infant nutrition. Their groundbreaking approach to life sciences aligns perfectly with our commitment to investing in transformative, science-based companies. We are excited to support their growth and contribute to the future of this exceptional international team originating from a leading Max Planck Institute.”

Technology Transfer Through Fundamental Research

eversyn is a spin-off of the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. The institute is dedicated to all aspects of process systems engineering, chemical, biochemical and energy systems, that are vital to the future of well-being of global society. The company’s emergence from the institute underscores the potential of fundamental research to foster technological advancements and economic growth through technology transfer and commercialization.

Dr. Lars Cuypers, Senior Patent & Licensing Manager, and Sebastian Meyer-Borchert, Senior Start-up Manager at Max Planck Innovation: “eversyn is a prime example of how cutting-edge fundamental research can evolve into a high-potential start-up. The team has successfully transformed a complex scientific concept into a viable business model with significant real-world applications. With its innovative technology platform, eversyn not only brings breakthrough science to industry but also demonstrates how effectively knowledge transfer can lead to impactful company creation. We are proud to have supported the team from the initial IP strategy to the successful closing of this funding round.”

Looking Ahead

With this new funding, eversyn will scale up its production capabilities, expand its team, enhance ongoing research and development efforts, and forge strategic partnerships. These initiatives will accelerate market entry and position eversyn as a key innovator in nutrition and biopharmaceutical solutions. The company remains committed to delivering impactful technologies that address critical global health challenges.

About bmp Ventures
With a track record of over 250 investments across nearly all technology segments, mainly in the early-stage phase, bmp Ventures is one of the most experienced venture capital investors in Germany. In addition to direct investments, bmp managed venture capital funds for institutions such as the KfW Banking Group and DEG, the German Investment and Development Corporation. Currently, bmp oversees the IBG funds in Saxony-Anhalt and employs approximately 20 experts across its Berlin and Magdeburg locations.

About IBG funds
The IBG funds, headquartered in Magdeburg, are the venture capital funds of the country of Saxony-Anhalt – they provide capital to young, innovative technology companies with sustainable and above average growth potential, based in Saxony-Anhalt. By the end of 2023, IBG launched the new venture capital fund, RKF IV, with a volume of 63 million euros. The fund is financed by the state and the European Union and invests in innovative startups in Saxony-Anhalt in the seed, early stage, and expansion. The IBG funds are managed by bmp Ventures AG.

Press contact

bmp Ventures AG
Josephine Gantze
– Marketing and Events –
Phone: +49 391 5328 140
jgantze@bmp.com